Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Receivables: 2010-2025

Historic Receivables for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $118.0 million.

  • Myriad Genetics' Receivables fell 6.13% to $118.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $496.6 million, marking a year-over-year increase of 4.35%. This contributed to the annual value of $121.2 million for FY2024, which is 6.04% up from last year.
  • As of Q3 2025, Myriad Genetics' Receivables stood at $118.0 million, which was down 13.87% from $137.0 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Receivables registered a high of $137.0 million during Q2 2025, and its lowest value of $91.3 million during Q4 2021.
  • Over the past 3 years, Myriad Genetics' median Receivables value was $118.1 million (recorded in 2024), while the average stood at $119.9 million.
  • The largest annual percentage gain for Myriad Genetics' Receivables in the last 5 years was 33.52% (2021), contrasted with its biggest fall of 8.10% (2021).
  • Myriad Genetics' Receivables (Quarterly) stood at $91.3 million in 2021, then climbed by 11.28% to $101.6 million in 2022, then climbed by 12.50% to $114.3 million in 2023, then climbed by 6.04% to $121.2 million in 2024, then fell by 6.13% to $118.0 million in 2025.
  • Its Receivables was $118.0 million in Q3 2025, compared to $137.0 million in Q2 2025 and $120.4 million in Q1 2025.